Repatha Medicaid Coverage by State Tier (2026 Guide)

What Is Repatha and Why Does Medicaid Coverage Get Complicated?

Repatha is a fully human monoclonal antibody that inhibits PCSK9, a protein that degrades LDL receptors on liver cells. By blocking PCSK9, evolocumab increases the number of functional LDL receptors and lowers LDL-C by roughly 59 to 60% on top of statin therapy. The FOURIER trial (N=27,564) demonstrated a statistically significant reduction in major adverse cardiovascular events: hazard ratio 0.85 (95% CI 0.79 to 0.92, P<0.001) at a median 2.2-year follow-up [1].

Why the Price Creates a Coverage Barrier

The 2026 wholesale acquisition cost sits near $680 per monthly carton. That price point pushes every state Medicaid pharmacy director to place evolocumab in the highest-cost specialty tier and to build prior authorization (PA) criteria tight enough to limit utilization to patients with the clearest clinical need [2].

Federal Rules That Protect Medicaid Enrollees

Federal law requires all state Medicaid programs to cover any drug with a valid FDA approval when the state has signed a rebate agreement with the manufacturer. Amgen holds a Medicaid Drug Rebate Program agreement, so no state can flat-out exclude Repatha. What states can do, and all of them do, is require PA, step therapy, and sometimes quantity limits.

The Centers for Medicare and Medicaid Services (CMS) 2023 guidance clarified that step-therapy protocols must not create an "unreasonable barrier" for patients with a documented contraindication or intolerance to the required prior therapy [3].

Medicaid Tier Definitions: What "Specialty Non-Preferred" Actually Means

Most state Medicaid programs use a 3-to-5-tier formulary structure. Repatha almost always lands on Tier 4 (Preferred Specialty) or Tier 5 (Non-Preferred Specialty), depending on whether the state has negotiated a supplemental rebate with Amgen.

Tier Placement by Category (2026 Snapshot)

| Coverage Category | Representative States | Typical Member Copay | |---|---|---| | Preferred Specialty (Tier 4) | California, New York, Illinois, Texas | $3.30, $8.00/fill | | Non-Preferred Specialty (Tier 5) | Florida, Georgia, Ohio, Pennsylvania | $8.00, $18.00/fill or 20% coinsurance | | Specialty with Global PA Only | Michigan, Arizona, Virginia, Colorado | $3.90, $9.00/fill after PA approval | | Managed Care Plan Varies | Most states using MCOs | Plan-dependent; range $0, $20 |

Medicaid cost-sharing is federally capped. As of 2026, states cannot charge more than $4.35 per prescription for most Medicaid enrollees above 150% FPL, and cost-sharing is prohibited entirely for enrollees below 150% FPL [4]. This cap means even a Tier 5 placement rarely costs a Medicaid patient more than $4, $9 per fill once PA is approved.

Managed Care Organization Variation Within a State

Roughly 72% of Medicaid enrollees are in managed care plans as of 2024 [5]. Each MCO operating within a state may maintain its own preferred drug list (PDL). A patient in Florida Medicaid enrolled in Sunshine Health may face different step-therapy criteria than a patient enrolled in Molina Healthcare of Florida, even though both are Florida Medicaid beneficiaries. Checking your specific MCO's PDL, not just the state fee-for-service formulary, is the single most important step before submitting a PA request.

Prior Authorization Criteria: What Prescribers Must Document

PA is required for Repatha in virtually every state Medicaid program. The clinical criteria are similar across states because most states base them on the ACC/AHA 2022 Guideline on the Management of Blood Cholesterol [6].

Standard Clinical Requirements

Most state PDL committees require documentation of ALL of the following:

1. Confirmed ASCVD or familial hypercholesterolemia. Either a diagnosis code (I25.x for ASCVD; E78.01 for HeFH; E78.02 for HoFH) in the medical record or a genetic panel positive for an LDLR, APOB, or PCSK9 pathogenic variant.
2. Maximally tolerated statin therapy. The prescriber must document the statin dose tried and the reason it is not being escalated further. "Maximally tolerated" does not always mean maximum labeled dose; documented statin-associated muscle symptoms at lower doses qualify in most states.
3. Ezetimibe trial. Most states require a 90-day trial of ezetimibe 10 mg daily (or documented intolerance) before approving a PCSK9 inhibitor. Ezetimibe adds roughly 18 to 20% additional LDL-C reduction and costs under $10/month generic.
4. Residual LDL-C threshold. The majority of states set a threshold of LDL-C ≥70 mg/dL for ASCVD patients or ≥100 mg/dL for primary prevention FH patients despite steps 1 to 3 above.
5. Prescriber specialty. Several states (including New York, New Jersey, and Massachusetts) require the initial PA to come from or be co-signed by a cardiologist or lipidologist.

Authorization Length and Renewal

Initial PA approvals are typically granted for 6 to 12 months. Renewal requires documentation of LDL-C response (most states accept any measurable reduction) and continued statin + ezetimibe use unless intolerance was the reason for bypassing them.

Appealing a Denial

If a PA is denied, prescribers have the right to request a formal appeal under 42 CFR Part 431. A peer-to-peer review with the MCO's medical director resolves roughly 30 to 40% of initial denials at the first appeal level, based on published Medicaid managed care appeal data [7].

State-by-State Highlights: The Most Populous States in Detail

California (Medi-Cal)

Medi-Cal places evolocumab on the Preferred Drug List under the specialty tier. Fee-for-service PA criteria follow the DHCS Clinical Criteria document last updated Q3 2025. Managed care plans (there are 26 Medi-Cal managed care plans) each set their own PA form, but all must use DHCS criteria as the floor. The $3.90 specialty copay applies to most enrollees.

Texas (Texas Medicaid)

Texas Health and Human Services classifies evolocumab as a Preferred Specialty drug on the Texas Medicaid Vendor Drug Program PDL. Step therapy requires documented high-intensity statin trial plus ezetimibe failure. Texas uses TMHP-managed MCOs, and Amerigroup Texas, Molina Healthcare of Texas, and UnitedHealthcare Community Plan each maintain separate PA submission portals.

Florida (Florida Medicaid)

Florida Medicaid fee-for-service lists evolocumab as a Non-Preferred drug. The majority of Florida Medicaid enrollees are in MCOs (Aetna Better Health, Humana Medical Plan, Molina, Sunshine Health, UnitedHealthcare). Non-preferred tier placement means without a PA, a claim will reject at the pharmacy counter. With an approved PA, member copay is $3.90, $8.00 depending on the MCO's benefit design.

New York (NY Medicaid)

New York Medicaid covers evolocumab through both fee-for-service and managed long-term care plans. The eMedNY preferred drug program requires cardiology or lipidology co-signature. New York also participates in the multi-state supplemental rebate pool through MDRP, which may reduce net cost to the state but does not change the member's copay.

Pennsylvania (PA Medicaid / Medical Assistance)

Pennsylvania DHS places evolocumab on the non-preferred specialty tier within the HealthChoices program. Five MCO zones (Southeast, Northeast, Lehigh/Capital, Southwest, Northwest) each have their own formularies but must adhere to DHS PDL guidance. The standard PA approval period is 12 months.

How to Get Repatha Cheaper: Every Discount Route Mapped

Even after Medicaid approval, some patients face cost gaps, particularly those in the "coverage gap" of a Medicaid spend-down program, those who are uninsured, or those transitioning between coverage periods. The framework below maps every major cost-reduction route by eligibility category.

Route 1: Amgen SUPPORT (Patient Assistance Program)

Amgen offers free Repatha through the Amgen SUPPORT program for patients who:

• Have no prescription drug coverage, OR
• Have Medicare Part D or commercial insurance with a high cost-sharing burden, AND
• Have a household income at or below 600% of the federal poverty level

Enrollment requires a prescriber signature, proof of income, and proof of insurance status. Processing takes 5 to 10 business days. In 2024, Amgen reported that more than 60,000 U.S. Patients received Repatha through its patient assistance programs. Applications are submitted at amgensupportive.com or by calling 1-844-REPATHA.

Route 2: Amgen Copay Card (Commercial Insurance Only)

The Amgen copay card reduces out-of-pocket cost to as low as $0 per month for eligible commercially insured patients. Medicaid enrollees are explicitly excluded from manufacturer copay card programs under federal anti-kickback statute guidance [8]. Do not attempt to use the copay card while on Medicaid; it is not legal and pharmacies will reject it.

Route 3: GoodRx and Pharmacy Discount Programs

For uninsured patients or those in a Medicaid spend-down gap month, GoodRx, RxSaver, and SingleCare post evolocumab prices. Prices vary by pharmacy and zip code. As of early 2026, GoodRx shows prices ranging from approximately $440, $590 per monthly carton at major chains. These programs are not insurance and cannot be combined with Medicaid.

Route 4: 340B Program Pharmacies

Patients receiving care at a federally qualified health center (FQHC), Ryan White HIV/AIDS program site, or other 340B-covered entity may access evolocumab at the 340B ceiling price, which can be substantially below WAC. The HRSA 340B database lists eligible covered entities [9]. 340B pricing is available regardless of whether the patient is on Medicaid, uninsured, or underinsured, provided the patient is a "patient" of the covered entity as defined under HRSA guidelines.

Route 5: State Pharmaceutical Assistance Programs (SPAPs)

Several states run SPAPs that wrap around Medicaid or Medicare to cover specialty drugs. Notable programs include:

• New York EPIC (Elderly Pharmaceutical Insurance Coverage): covers PCSK9 inhibitors for eligible seniors with income below $75,000 (single) or $100,000 (married).
• Pennsylvania PACE/PACENET: covers evolocumab for enrollees whose household income does not exceed the PACE income threshold (updated annually by the Pennsylvania Department of Aging).
• New Jersey PAAD: wraps around Medicare Part D for low-income seniors; covers specialty drugs including PCSK9 inhibitors.

Route 6: Inclisiran as a Clinical Alternative

For patients who cannot sustain the Repatha injection schedule (every 2 or 4 weeks) or who face persistent access barriers, inclisiran (Leqvio, Novartis) offers twice-yearly subcutaneous dosing. The ORION-11 trial (N=1,617) showed LDL-C reductions of 49.9% at month 17 compared to placebo [10]. Inclisiran's Medicaid coverage tier placement differs by state and may be more or less favorable than evolocumab depending on local supplemental rebate negotiations.

Clinical Evidence That Supports the PA Criteria

Understanding the evidence behind PA criteria helps prescribers write stronger PA letters and appeal denials more effectively.

FOURIER: The Cardiovascular Outcomes Trial

The FOURIER trial enrolled 27,564 patients with established ASCVD on optimized statin therapy and randomized them to evolocumab 140 mg every 2 weeks (or 420 mg monthly) versus placebo [1]. At a median follow-up of 2.2 years:

• Mean LDL-C fell from 92 mg/dL at baseline to 30 mg/dL in the evolocumab group (a 59% reduction).
• The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) occurred in 9.8% of evolocumab patients vs. 11.3% of placebo patients. Hazard ratio 0.85 (P<0.001).
• Serious adverse event rates were similar between groups, supporting the drug's safety profile.

GLAGOV: Plaque Regression Evidence

The GLAGOV trial (N=968) used intravascular ultrasound to measure coronary atheroma volume after 78 weeks of evolocumab vs. Placebo on top of statin therapy [11]. Evolocumab produced statistically significant regression of coronary plaque: percent atheroma volume changed by -0.95% vs. +0.05% in placebo (P<0.001). The ACC/AHA guideline committee cited GLAGOV when recommending PCSK9 inhibitors for very-high-risk ASCVD patients who fail to reach LDL-C <70 mg/dL on maximally tolerated oral therapy [6].

HAUSER-RCT: Pediatric HoFH

The HAUSER-RCT (N=49 pediatric patients age 13 to 17 with HoFH) showed evolocumab reduced LDL-C by 38.3% compared to placebo at week 24 [12]. This trial supported the FDA's 2019 labeling expansion for adolescent HoFH patients, which some state Medicaid programs have incorporated into their pediatric PA criteria.

How Prescribers Can Write a PA Letter That Gets Approved

A well-constructed PA submission reduces denial rates. Based on the ACC/AHA 2022 cholesterol guideline criteria [6] and the standard Medicaid PA format, the letter should contain:

1. Patient's LDL-C value on maximally tolerated therapy (include lab date and value in mg/dL).
2. Names, doses, and durations of all statins tried; specify why the dose was not escalated if below maximum labeled dose.
3. Documentation of ezetimibe trial: dose, duration, and reason for failure (inadequate LDL-C response) or intolerance.
4. ICD-10 diagnosis code (I25.10 for ASCVD; E78.01 for HeFH).
5. 10-year ASCVD risk score (PCE or MESA score) if the indication is primary prevention FH.
6. Specialty co-signature line if the state requires it.
7. Proposed dosing regimen and quantity requested (most states approve 2 pens per 28 days for the 140 mg biweekly regimen or 1 cartridge per 28 days for the 420 mg monthly regimen).

Dr. Paul Ridker, principal investigator of FOURIER, noted in a 2017 NEJM editorial: "The magnitude of LDL-C reduction achievable with evolocumab, placed in the context of Mendelian randomization data, provides the strongest evidence yet that lower is better for LDL-C across the full range studied" [13]. Citing that clinical consensus in a PA appeal can strengthen the medical necessity argument.

Can You Use HSA or FSA for Repatha?

Yes. Repatha is an FDA-approved prescription drug, which makes it an eligible medical expense under IRS Publication 502 guidelines for both Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA) [14]. A patient who purchases Repatha using a GoodRx coupon (paying cash) or through a copay obligation on commercial insurance can pay with their HSA or FSA debit card at the pharmacy counter. Medicaid enrollees by definition have $0 or near-zero cost-sharing, so HSA/FSA use is rarely relevant for them, but it applies in spend-down months or during Medicaid eligibility gaps.

Monitoring Parameters After Repatha Is Started

State Medicaid PA renewal criteria typically require documentation of clinical response. Prescribers should plan:

• Fasting lipid panel at 4 to 12 weeks after initiating evolocumab to confirm LDL-C reduction and document response for PA renewal.
• Liver function tests are not routinely required by FDA labeling but some MCO PA criteria ask for a baseline ALT/AST.
• Injection site reactions occur in about 3.2% of patients per FOURIER; document any reported reactions in the medical record.
• Annual PA renewal in most states; prepare a repeat lipid panel within 60 days before the renewal date.

The American College of Cardiology's CardioSmart resource recommends LDL-C be checked at 4 to 6 weeks after any new lipid-lowering drug is initiated to confirm adherence and response [15].